TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9530159
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) 80 mg/kg
Study: 2499527
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no CHPP‐M treatment)
Study: 20592050
Drug: Initiating insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initiating insulin as part of the Treating To Target in Type 2 Diabetes (4-T) trial
Study: 18320867
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day plus esterified conjugated estrogens 0.312 mg/day
Study: 7594334
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg q.d. (n = 10)
Study: 7594334
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg b.i.d. (n = 10)
Study: 2179066
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg after evening meal
Study: 2179066
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg before evening meal
Study: 2179066
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg with snacks allowed
Study: 2179066
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg with snacks forbidden
Study: 6783419
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid administration
Study: 25567841
Drug: 40% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% of the standard dose of IPV intradermally
Study: 25567841
Drug: 20% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% of the standard dose intradermally
Study: 25567841
Drug: full standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: full standard dose intramuscularly
Study: 25567841
Drug: 40% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% of the standard dose intramuscularly
Study: 21887214
Drug: artemether-lumefantrine (A/L)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: artemether-lumefantrine (A/L)
Study: 19454737
Drug: Other blood
Normalized name: Other blood products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other blood pressure lowering drugs
Study: 19454737
Drug: Three drugs
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three drugs at half standard dose
Study: 19454737
Drug: Other blood
Normalized name: Other blood products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other blood pressure lowering drugs (excluding non-cardioselective β blockers)
Study: 17574482
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 5 ml of 5% NaOCl + 2.5 ml of 3.6% H(2)O(2)
Study: 17574482
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 5 ml of 5% NaOCl + 2.5 ml of 17% ethylenediamine tetraacetic acid
Study: 15043765
Drug: New-generation antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: New-generation antipsychotics (risperidone, olanzapine, quetiapine, ziprasidone, sertindole, amisulpride, aripiprazole)
Study: 15043765
Drug: New-generation antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: New-generation antipsychotics
Study: 3121836
Drug: 24 h
Normalized name: Immune 24 Hour +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 h infusion of phosphate
Study: 3121836
Drug: 24 h
Normalized name: Immune 24 Hour +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 h infusion of calcium
Study: 25391865
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 120 kVp with 350 mgI/ml iodinated contrast agent
Study: 25391865
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 100 kVp with 350 mgI/ml iodinated contrast agent
Study: 25391865
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 100 kVp with 270 mgI/ml iodinated contrast agent
Study: 23868011
Drug: Anastrozole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (3 additional years of treatment)
Study: 23868011
Drug: Nil (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nil (no additional treatment)
Study: 16015270
Drug: Butter (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butter (40 g daily for 4 weeks)
Study: 16015270
Drug: Cheese (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cheese (40 g daily for 4 weeks)
Study: 11849857
Drug: Treatment >2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment >2 h after symptoms onset
Study: 1665182
Drug: Lisinopril-hydrochlorothiazide (L/HCTZ)
Normalized name: fosinopril / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril-hydrochlorothiazide (L/HCTZ)
Study: 2789927
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of oxytocin
Study: 25881049
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (transfuse if haemoglobin concentration <7.5 g/dl)
Study: 25881049
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (transfuse if haemoglobin concentration <9 g/dl)
Study: 17042886
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg/day) with lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Study: 17042886
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Study: 10902861
Drug: Ferric trimaltol
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric trimaltol (four different pharmaceutical formulations)
Study: 9068464
Drug: OBTM‐2 (bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBTM‐2 (bismuth subcitrate 240 mg, tetracycline 500 mg, metronidazole 400 mg four times daily for 2 days)
Study: 9068464
Drug: OBTM‐7 (bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBTM‐7 (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg four times daily for 1 wk)
Study: 8453956
Drug: rac-felodipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rac-felodipine (20 mg solution p.o.)
Study: 8453956
Drug: rac-nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rac-nitrendipine (20 mg solution p.o.)
Study: 8453956
Drug: nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (20 mg solution p.o.)
Study: 28985434
Drug: Oxytocin administration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administration (24 IU)
Study: 29228315
Drug: nab-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 125 mg/m2/gemcitabine 1000 mg/m2 d1,8 three times weekly (q3w)
Study: 29228315
Drug: nab-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 125 mg/m2/carboplatin AUC2 day 1,8 q3w
Study: 27128532
Drug: One-quarter standard-dose
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-quarter standard-dose ticagrelor (22.5 mg BID for 7 days)
Study: 27128532
Drug: Standard-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose clopidogrel (75 mg QD for 7 days)
Study: 22623230
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of omega-3 ethyl esters for 1 month
Study: 19353351
Drug: Salmeterol/Fluticasone Propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/Fluticasone Propionate combination (SFC)
Study: 15716083
Drug: Levetiracetam 3000
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 3000 mg/day (administered bid)
Study: 11154059
Drug: Laser acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser acupuncture treatment
Study: 8878586
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of hypericin and pseudohypericin
Study: 8878586
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Hypericum extract
Study: 8878586
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of Hypericum extract
Study: 1904750
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ritanserin
Study: 1904750
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg ritanserin
Study: 1904750
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ritanserin
Study: 6309882
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ketoconazole
Study: 6309882
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ketoconazole (chronic administration)
Study: 24864639
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of 2% prilocaine
Study: 24864639
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of 2% prilocaine + 8 mg of dexamethasone (2 ml)
Study: 24864639
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg 0.5% levobupivacaine
Study: 17299059
Drug: Open-label adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Open-label adalimumab 40 mg every other week
Study: 15214257
Drug: Lysine-fortified wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine-fortified wheat flour (3 g of lysine per kilogram for three months)
Study: 10223239
Drug: C +
Normalized name: Probiotic + Colostrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C + D + T (Carboplatin 300 mg/m2, Dacarbazine 1 g/m2, Tamoxifen 20 mg/day)
Study: 10223239
Drug: C +
Normalized name: Probiotic + Colostrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C + D (Carboplatin 300 mg/m2, Dacarbazine 1 g/m2)
Study: 8536512
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme substitution preparation
Study: 2571460
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of vecuronium
Study: 2571460
Drug: Hourly boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hourly boluses of vecuronium
Study: 224478
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus BCG
Study: 27587469
Drug: Ipilimumab (single-dose)
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab (single-dose)
Study: 24657311
Drug: Chemical imbalance
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical imbalance test feedback (bogus biological test results)
Study: 31127467
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (AI)
Study: 16330887
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (AI) after 2-3 years of tamoxifen
Study: 16330887
Drug: Continuing aromatase
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing aromatase inhibitors (AI) after 5 years of tamoxifen
Study: 11881981
Drug: Tenoxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (20 mg single-dose and 12 days repeated-dose)
Study: 9662319
Drug: Intracervical Foley
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical Foley catheter/intravaginal dinoprostone 4 mg every 4 hours
Study: 947510
Drug: Weekly combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly combination of cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, and prednisone
Study: 947510
Drug: Intermittent combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent combination of the same five drugs given in courses of 5 days repeated every 4 weeks
Study: 947510
Drug: Adriamycin as
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin as a single agent every 3 weeks
Study: 31599746
Drug: Aspirin group
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin group (discontinued thienopyridines for 1 week)
Study: 20301883
Drug: Spironolactone therapy
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone therapy (25 mg/day for 20 days) in Group A (smoking patients)
Study: 20301883
Drug: Spironolactone therapy
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone therapy (25 mg/day for 20 days) in Group B (non-smoking patients)
Study: 17940723
Drug: Treatment slowing
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment slowing atrophy rate by 30%
Study: 9736234
Drug: Treatment partly
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment partly in a training apartment with problem-based education and special therapeutic support
Study: 3190970
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 75 mg kg‐1
Study: 3190970
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 25 mg kg‐1
Study: 3190970
Drug: Midazolam 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.4 mg kg‐1
Study: 3190970
Drug: Midazolam 0.4-0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.4-0.5 mg kg‐1
Study: 3190970
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (all doses)
Study: 3190970
Drug: Midazolam (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (all doses)
Study: 3190970
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of both premedicants
Study: 31515843
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of 1.5 g of cefuroxime
Study: 31515843
Drug: Short-term infusion
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term infusion (STI) of 1.5 g of cefuroxime
Study: 26077459
Drug: Therapeutic regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic regimen of Traditional Chinese Medicine (TCM) rehabilitation
Study: 23528400
Drug: Licopid as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licopid as immunocorrective agent
Study: 23528400
Drug: Antifungal and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal and antimicrobial treatment, eubiotics and bacteriophages
Study: 16685010
Drug: Terbutaline, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline, 0.5 mg
Study: 3332610
Drug: Bromocriptine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine at doses up to 20 mg/day
Study: 27287699
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg every 4 weeks plus placebo
Study: 27287699
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg every 4 weeks plus ezetimibe
Study: 27287699
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg every 4 weeks plus fenofibrate
Study: 16022756
Drug: Fermented soya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented soya milk (40 mg isoflavone)
Study: 16022756
Drug: Increasing isoflavone
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing isoflavone dosage
Study: 16022756
Drug: Modest dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modest dosage (20-30 mg/d)
Study: 14727988
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate 200 mg/day (capsules)
Study: 14727988
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate 160 mg once daily (tablet)
Study: 14727988
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate (tablet and capsule formulations)
Study: 7781149
Drug: Oral trofosfamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trofosfamide, escalated doses every 3rd week until grade 2 leukopenia
Study: 2281055
Drug: Amiloride inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride inhalation (0.3 mg/ml)
Study: 24453924
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline inhalation
Study: 31503309
Drug: Multicomponent home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent home-based physical therapy intervention (training)
Study: 28911357
Drug: Combination intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination intervention package to improve early initiation of ART and anti-tuberculosis treatment success
Study: 17940861
Drug: Integrated individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated individual cognitive-behavioral treatment and HIV prevention intervention
Study: 16219571
Drug: Delayed intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed intensification followed by maintenance chemotherapy
Study: 7547040
Drug: Spinal amethocaine
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal amethocaine 12 mg in 2 ml of 5% glucose
Study: 7547040
Drug: Spinal amethocaine
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal amethocaine 14 mg in 2 ml of 5% glucose
Study: 7547040
Drug: Spinal amethocaine
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal amethocaine 8 mg in 2 ml of 5% glucose
Study: 1540304
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (15 mg bid, po)
Study: 3886712
Drug: Arildone in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arildone in vanishing cream
Study: 3886712
Drug: Arildone in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arildone in DMSO solution
Study: 3886712
Drug: Vanishing cream
Normalized name: Vanishing Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanishing cream vehicle without arildone
Study: 3886712
Drug: DMSO solution
Normalized name: DMSO
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DMSO solution vehicle without arildone
Study: 30053897
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal oxygen therapy (HFNO2)
Study: 30053897
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen therapy (standard low flow oxygen therapy)
Study: 27026675
Drug: Trastuzumab (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (high dose: 8 mg/kg)
Study: 27026675
Drug: Trastuzumab (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (low dose: 4 mg/kg)
Study: 21116604
Drug: GAD‐alum (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD‐alum (20 μg subcutaneous injection at baseline and 1 month later)
Study: 21116604
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous injection at baseline and 1 month later)
Study: 9695723
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine 21 mg/24 hr
Study: 9695723
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine 42 mg/24 hr
Study: 9695723
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine 63 mg/24 hr
Study: 9695723
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (all doses)
Study: 9695723
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine with smoking
Study: 7626984
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (erythropoietin + calcitriol)
Study: 7626984
Drug: Erythropoietin monotherapy
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin monotherapy
Study: 31996953
Drug: Interferon beta/interleukin-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta/interleukin-2 immunotherapy added to first-line salvage hormone therapy (HT)
Study: 31996953
Drug: Historical controls
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical controls receiving first-line salvage hormone therapy (HT)
Study: 28964890
Drug: ABT‐981 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐981 (0.3, 1, or 3 mg/kg) every other week for a total of four SC injections
Study: 28964890
Drug: ABT‐981 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐981 (3 mg/kg) every 4 weeks for a total of three SC injections